DK3287787T3 - Anti-tumorrespons til modificerede selv-epitoper - Google Patents

Anti-tumorrespons til modificerede selv-epitoper Download PDF

Info

Publication number
DK3287787T3
DK3287787T3 DK17194251.9T DK17194251T DK3287787T3 DK 3287787 T3 DK3287787 T3 DK 3287787T3 DK 17194251 T DK17194251 T DK 17194251T DK 3287787 T3 DK3287787 T3 DK 3287787T3
Authority
DK
Denmark
Prior art keywords
epitopes
tumor response
modified self
self
modified
Prior art date
Application number
DK17194251.9T
Other languages
English (en)
Inventor
Rachel Louise Metheringham
Linda Gillian Durrant
Victoria Anne Brentville
Original Assignee
Scancell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Ltd filed Critical Scancell Ltd
Application granted granted Critical
Publication of DK3287787T3 publication Critical patent/DK3287787T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
DK17194251.9T 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selv-epitoper DK3287787T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1214007.5A GB201214007D0 (en) 2012-08-07 2012-08-07 Anti-tumour immune responses to modified self-epitopes
EP13750368.6A EP2883054B1 (en) 2012-08-07 2013-08-07 Anti-tumour response to modified self-epitopes

Publications (1)

Publication Number Publication Date
DK3287787T3 true DK3287787T3 (da) 2020-12-21

Family

ID=46934958

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17194252.7T DK3301447T3 (da) 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selvepitoper
DK17194251.9T DK3287787T3 (da) 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selv-epitoper
DK13750368.6T DK2883054T3 (da) 2012-08-07 2013-08-07 Antitumor-respons på modificerede selv-epitoper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17194252.7T DK3301447T3 (da) 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selvepitoper

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13750368.6T DK2883054T3 (da) 2012-08-07 2013-08-07 Antitumor-respons på modificerede selv-epitoper

Country Status (18)

Country Link
US (4) US10233220B2 (da)
EP (3) EP3287787B1 (da)
JP (2) JP6490581B2 (da)
KR (1) KR102203096B1 (da)
CN (2) CN104823054B (da)
AU (1) AU2013301341B2 (da)
BR (1) BR112015002574A8 (da)
CA (1) CA2874515A1 (da)
DK (3) DK3301447T3 (da)
ES (3) ES2681973T3 (da)
GB (1) GB201214007D0 (da)
HK (1) HK1206427A1 (da)
IN (1) IN2014DN10629A (da)
PL (2) PL3287787T3 (da)
PT (3) PT3301447T (da)
SG (2) SG11201407804RA (da)
WO (1) WO2014023957A2 (da)
ZA (1) ZA201409095B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
DK3140323T3 (da) 2014-05-05 2018-07-23 Novio Th B V Fremgangsmåde til serologisk diagnosticering af rheumatoid arthritis.
CN104360070B (zh) * 2014-11-28 2017-02-22 山东新创生物科技有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
GB201512703D0 (en) * 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2018046648A1 (en) * 2016-09-08 2018-03-15 Katholieke Universiteit Leuven Citrullinated peptides for diagnosis or treatment of diabetes
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
TW202012430A (zh) 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質－結合之胜肽組成物及其使用方法
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
CN114404570B (zh) * 2022-01-20 2023-05-30 中国药科大学 一种新型抗肿瘤转移多肽及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002051785A (ja) * 2000-08-09 2002-02-19 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体ＣＬＮ−ＩｇＧによって認識される抗原エピトープのアミノ酸配列およびそれをコードするＤＮＡヌクレオチド配列
WO2002034287A2 (en) * 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
EP1461001A4 (en) * 2002-01-03 2010-03-31 Scripps Research Inst EPITOPE ASSOCIATED WITH CANCER
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
CN100347191C (zh) * 2002-10-02 2007-11-07 霍夫曼-拉罗奇有限公司 新mhcⅱ相关肽
US7670604B2 (en) * 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP1695089A1 (en) * 2003-12-15 2006-08-30 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
DE102005029845B4 (de) * 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
CN1712964A (zh) * 2005-07-18 2005-12-28 山东省医药生物技术研究中心 类风湿性关节炎特异性抗原性标志物及其应用
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8653039B2 (en) * 2006-02-17 2014-02-18 Robert J. Hickey Peptide based inhibition of caPCNA interaction in cancer
WO2007098093A2 (en) * 2006-02-17 2007-08-30 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
US20070248539A1 (en) * 2006-04-24 2007-10-25 Shantha West Inc. AgRM2 antigen
EP1882697B1 (en) * 2006-07-24 2010-04-21 Institut Pasteur Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
EP2249865A4 (en) * 2008-02-08 2012-04-04 Scripps Research Inst RUPTURE OF IMMUNOLOGICAL TOLERANCE WITH GENETICALLY CODED NON-NATURAL AMINO ACID
NZ608489A (en) * 2009-03-30 2014-08-29 Nestec Sa Citrullinated peptides for diagnosing and prognosing rheumatiod arthritis
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
EP2663320A1 (en) 2011-01-10 2013-11-20 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2667888A4 (en) 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2694530B1 (en) 2011-04-05 2018-02-14 Curara AB Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment
US20120295292A1 (en) * 2011-05-19 2012-11-22 University Of South Carolina Detecting Protein Arginine Deiminase (PAD) Activity in Human Tissues and Sera
US20130274125A1 (en) * 2012-04-16 2013-10-17 Bio-Rad Laboratories Inc. Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes

Also Published As

Publication number Publication date
EP3301447A1 (en) 2018-04-04
US20150232525A1 (en) 2015-08-20
KR20150040314A (ko) 2015-04-14
DK2883054T3 (da) 2018-09-17
HK1206427A1 (en) 2016-01-08
IN2014DN10629A (da) 2015-09-11
AU2013301341A1 (en) 2014-12-18
PL3287787T3 (pl) 2021-06-14
JP2018197236A (ja) 2018-12-13
ES2681973T3 (es) 2018-09-17
SG10201701001VA (en) 2017-05-30
JP2015525569A (ja) 2015-09-07
WO2014023957A3 (en) 2014-05-15
US20230192790A1 (en) 2023-06-22
EP3287787B1 (en) 2020-09-23
PL3301447T3 (pl) 2021-09-06
CN104823054B (zh) 2019-03-26
PT2883054T (pt) 2018-10-15
US20180346537A1 (en) 2018-12-06
KR102203096B1 (ko) 2021-01-14
EP2883054A2 (en) 2015-06-17
ES2833962T3 (es) 2021-06-16
DK3301447T3 (da) 2021-03-08
PT3287787T (pt) 2020-11-26
EP3287787A1 (en) 2018-02-28
AU2013301341B2 (en) 2018-09-20
CA2874515A1 (en) 2014-02-13
EP3301447B1 (en) 2020-12-02
JP6490581B2 (ja) 2019-03-27
GB201214007D0 (en) 2012-09-19
US10233220B2 (en) 2019-03-19
ZA201409095B (en) 2016-09-28
CN104823054A (zh) 2015-08-05
PT3301447T (pt) 2021-02-18
BR112015002574A8 (pt) 2018-01-23
EP2883054B1 (en) 2018-06-13
US20210198334A1 (en) 2021-07-01
CN107043414A (zh) 2017-08-15
ES2843777T3 (es) 2021-07-20
WO2014023957A2 (en) 2014-02-13
SG11201407804RA (en) 2015-02-27
BR112015002574A2 (pt) 2017-11-07

Similar Documents

Publication Publication Date Title
DK3287787T3 (da) Anti-tumorrespons til modificerede selv-epitoper
SMT201700065B (it) Derivato piridonico
BR302012006143S1 (pt) Configuração aplicada em cadeira
DK2888010T3 (da) Fremgangsmåder til at hæmme fascin
BR302012003683S1 (pt) Configuração aplicada em poltrona
FR2988072B1 (fr) Aeronef
FR2995782B1 (fr) Sucres anti-pelliculaires
FR2985656B1 (fr) Oxymetre
ES1080381Y (es) Fachada de medios
BR302013002316S1 (pt) Configuração aplicada em cadeiras
BR302012005562S1 (pt) Configuração aplicada em cadeira
BR302012005268S1 (pt) Configuração aplicada em cadeira
BR302012005574S1 (pt) Configuracao aplicada em cadeira
BR302012005158S1 (pt) Configuração aplicada em cadeira
BR302012004460S1 (pt) Configuracao aplicada em cadeira
BR302012001611S1 (pt) Configuração aplicada em cadeira
FR2993908B1 (fr) Structure poteau-plateau
UA25744S (uk) Крісло
UA25008S (uk) Набір меблів
FI20130081A (fi) Rinnankytketty Lednauha
ITRM20120442A1 (it) Interfaccia paziente-struttura sanitaria
ES1077190Y (es) Escuadra desmontable
FI9912U1 (fi) Sängynpeite
ITPD20120048U1 (it) Struttura di barbecue
BR302012004499S1 (pt) Configuracao aplicada em mictório